Bright Minds Biosciences (DRUG) News Today $31.25 -1.42 (-4.35%) (As of 10:31 AM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Bright Minds Biosciences participates in a conference call with TruistNovember 20 at 10:25 PM | markets.businessinsider.comBright Minds Biosciences Closes US$35 Million Non-Brokered Private PlacementNovember 4, 2024 | globenewswire.comBright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market PotentialOctober 30, 2024 | seekingalpha.comShort Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 1,274.9%Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 1,170,000 shares, an increase of 1,274.9% from the September 30th total of 85,100 shares. Approximately 38.2% of the company's stock are short sold. Based on an average trading volume of 2,890,000 shares, the short-interest ratio is currently 0.4 days.October 25, 2024 | marketbeat.comSteven Cohen's Strategic Acquisition of Bright Minds Biosciences Inc SharesOctober 24, 2024 | uk.finance.yahoo.comCormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences SharesOctober 23, 2024 | finance.yahoo.comBright Minds and Firefly Neuroscience Renew CollaborationOctober 22, 2024 | markets.businessinsider.comBright Minds, Firefly Neuroscience to collaborate after BREAKTHROUGH studyOctober 22, 2024 | markets.businessinsider.comWhat's Going On With Bright Minds Biosciences Stock?October 22, 2024 | msn.comBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG DataOctober 21, 2024 | globenewswire.comMarketBeat Week in Review – 10/14 - 10/18 (DRUG)Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.October 19, 2024 | marketbeat.comBright Minds rebounds after $35M private placementOctober 18, 2024 | msn.comWhat's Going On With Bright Minds Biosciences Stock Friday?October 18, 2024 | msn.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Major Shareholder Cormorant Asset Management, Lp Acquires 372,591 SharesOctober 18, 2024 | insidertrades.comBright Minds Biosciences Announces US$35 Million Non-Brokered Private PlacementOctober 18, 2024 | globenewswire.comCormorant Asset Management, Lp Purchases 372,591 Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG) StockBright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) major shareholder Cormorant Asset Management, Lp acquired 372,591 shares of the stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average price of $5.53 per share, for a total transaction of $2,060,428.23. Following the completion of the acquisition, the insider now directly owns 825,000 shares of the company's stock, valued at $4,562,250. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.October 17, 2024 | marketbeat.comPerceptive Advisors LLC Acquires New Stake in Bright Minds Biosciences IncOctober 16, 2024 | finance.yahoo.comBright Minds Biosciences Inc Ordinary SharesOctober 16, 2024 | morningstar.comBright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain modelsOctober 16, 2024 | globenewswire.comBright Minds Biosciences Stock Surges Almost 1,500%Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news.October 16, 2024 | marketbeat.comBiotech stock tumbles after unexplained 1,446% gainOctober 16, 2024 | msn.comBright Minds Biosciences announces participation in upcoming scientific conferences and partnering eventsOctober 3, 2024 | globenewswire.comBright Minds Biosciences Inc Ordinary Shares DRUGOctober 3, 2024 | morningstar.comBright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thSeptember 19, 2024 | globenewswire.comBright Minds Biosciences launches Phase II trial of absence epilepsy treatmentSeptember 14, 2024 | msn.comBright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic EncephalopathySeptember 12, 2024 | prnewswire.comBright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D EffortsAugust 16, 2024 | benzinga.comMedical journal retracts three articles related to MDMA for PTSDAugust 12, 2024 | msn.comPsyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And MoreJanuary 12, 2024 | msn.comBright Minds Announces Non-Brokered Private Placement Fully Subscribed by ManagementDecember 6, 2023 | finance.yahoo.comPsyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & MoreNovember 12, 2023 | msn.comBright Minds Biosciences Inc. (DRUG.CN)November 12, 2023 | finance.yahoo.comBright Minds Biosciences Stock (NASDAQ:DRUG) Dividends: History, Yield and DatesOctober 25, 2023 | benzinga.comDRUG Bright Minds Biosciences Inc.August 18, 2023 | seekingalpha.comBright Minds stock rallies ahead of conference call to discuss Phase 1 dataAugust 8, 2023 | msn.comBright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101August 8, 2023 | finance.yahoo.comBright Minds reports results from trial to treat refractory epilepsiesAugust 7, 2023 | msn.comCybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical TrialsJuly 24, 2023 | benzinga.comBright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101July 20, 2023 | finance.yahoo.comBright Minds Biosciences Stock (NASDAQ:DRUG), Short Interest ReportJuly 12, 2023 | benzinga.comBright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ ComplianceJuly 11, 2023 | msn.comBright Minds Biosciences: Bright Minds Announces Effective Date of Share ConsolidationJuly 11, 2023 | finanznachrichten.deBright Minds Biosciences: Bright Minds Announces Proposed Share ConsolidationJune 22, 2023 | finanznachrichten.deBright Minds Announces Proposed Share ConsolidationJune 22, 2023 | finance.yahoo.comBright Minds Biosciences Stock (NASDAQ:DRUG), Earnings Estimates, EPS, and RevenueMay 16, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG), Analyst Ratings, Price Targets, PredictionsApril 20, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG), Trade IdeasApril 19, 2023 | benzinga.comBright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202April 19, 2023 | finance.yahoo.comBright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin ResearchApril 10, 2023 | finance.yahoo.comBright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023February 27, 2023 | finance.yahoo.com Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. DRUG Media Mentions By Week DRUG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRUG News Sentiment▼0.000.46▲Average Medical News Sentiment DRUG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRUG Articles This Week▼10▲DRUG Articles Average Week Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Annexon News Today GH Research News Today ABIVAX Société Anonyme News Today Sana Biotechnology News Today Organogenesis News Today Astria Therapeutics News Today Corvus Pharmaceuticals News Today PureTech Health News Today Monte Rosa Therapeutics News Today Mereo BioPharma Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRUG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
